News

Sarepta upgraded to Neutral at J.P. Morgan, Outperform at Oppenheimer
Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.
Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments
Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...
North American Morning Briefing: Stock Futures Rise as Investors Weigh Trade Talks, Earnings
-U.S. futures for the S&P 500 and Dow Jones Industrial Average rose 0.1% and Nasdaq futures gained 0.3%. Earnings will come today from Boeing, Spotify, United Health, Procter & Gamble, Visa and PayPal ...
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and ...
Sarepta will resume gene therapy shipments after FDA review of recent patient death
Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would ...